Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system.
Our most clinically advanced product candidates are derived from our proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Our PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.
We currently have three PharmacoSurgery programs in clinical development. We have two lead product candidates, OMS103HP for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain and OMS302 for use during ophthalmological procedures to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain. OMS302 successfully completed a Phase 3 clinical program and we are now seeking marketing approval for this product. OMS103HP is being evaluated in a Phase 3 clinical program.
In addition to our PharmacoSurgery platform, we have leveraged our expertise in inflammation, coagulopathies and the central nervous system to build a deep and diverse pipeline of preclinical programs targeting large markets. We have retained all manufacturing, marketing and distribution rights for each of our product candidates and programs.